SXTP Stock — 60 Degrees Pharmaceuticals, Inc. Common Stock

60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)

Updated October 16, 2026.

SXTP is a Stock. Total return is -99.9% over the past 3.3 years, 178.0 points behind SPY at 78.1%.

60 Degrees Pharmaceuticals is a specialty pharmaceutical company developing and commercializing therapies for infectious diseases, with its approved product Arakoda for malaria prevention and a pipeline including tafenoquine candidates in clinical trials for conditions such as babesiosis, fungal pneumonias, and COVID-19 indications, as well as celgosivir for viral infections. The company does not currently distribute to shareholders. This security appeals to growth-oriented investors willing to accept the substantial risks inherent in early-stage pharmaceutical development.

SXTP performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.9% over the past 3.3 years, 178.0 points behind SPY at 78.1%. Over the past year its total return — price change plus distributions reinvested — is -85.7%. Its deepest 1-year drawdown was 85.9%.

SXTP key facts

Asset type

Stock

Asset class

Equity

Inception date

07/12/2023

Distribution frequency

None

Last close

$0.86 (as of 2026-10-16)

Market cap

$3,008,432

Average volume

10064.0

Beta

2.537

Payout ratio

0.0%

EPS

$-2.51

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

SXTP risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 85.9%.

Who may consider SXTP — and who may not

It is a weaker fit for investors who need monthly cash flow (SXTP does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on SXTP

• All tickers starting with S

Tagged: Healthcare.

Frequently asked questions